Scientists use optical imaging to find deep cancers in their earliest stages

MIT researchers have developed a near-infrared imaging technique that can detect tumors deep in internal tissue before the cancer grows beyond a few hundred cells.

A co-lead author of the preclinical study describing the work, Angela Belcher, PhD, told MIT News the system can track a 0.1-millimeter fluorescent probe to a tissue depth of 8 centimeters—“far deeper than any existing biomedical optical imaging technique.”

The team hopes to take the technology to oncology imaging specialists who may be able to tap it for early diagnosis of ovarian and other cancers that are hard to find until they’ve progressed to late stages, according to the news item.

The novel system uses hyperspectral imaging, which works with multiple wavelengths of light. Belcher and colleagues tested their hyperspectral technique by injecting fluorescent probes into rodents. They found the probes provided useful anatomic information through the entire animal.

Guosong Hong, PhD, a materials scientist at Stanford who was not involved in the research, told MIT News he believes the new method is “game-changing.”

“For the first time, fluorescent imaging has approached the penetration depth of CT and MRI, while preserving its naturally high resolution, making it suitable to scan the entire human body,” Hong said.

The study was published online March 7 in Scientific Reports. To get the gist from MIT News, click below:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.